vicept - n. from Latin vita- life; and receptus (recipere) - to take back
A privately held specialty biopharmaceutical start-up focused on creating products for use in the largest and fastest growing sectors of the dermatology market.
Company founded with the mission to develop the first effective topically-applied treatment for the erythema (skin redness) associated with rosacea.
Innovator in the development of (
)-adrenergic receptor technology pursuing indications which include the treatment and prevention of Rosacea, Actinic (Solar) Purpura and peri-procedural bruising of the skin.
Recent News
August 25, 2010
Vicept Therapeutics selected for Life Science Award.
August 05, 2010
Vicept Therapeutics Announces Positive Clinical Study Results of V-101 for the Treatment of the Erythema of Rosacea.
June 30, 2010
Vicept Therapeutics Secures $10 Million to Complete Series A Funding
